Status:

ACTIVE_NOT_RECRUITING

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

Lead Sponsor:

Carisma Therapeutics Inc

Conditions:

HER2-positive

Adenocarcinoma

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

Phase 1, first-in-human, open label study of CAR macrophages in HER2 overexpressing solid tumors.

Detailed Description

A Phase 1, First in Human Study of Adenovirally Transduced Autologous Macrophages Engineered to Contain an Anti-HER2 Chimeric Antigen Receptor in Subjects with HER2 Overexpressing Solid Tumors Main S...

Eligibility Criteria

Inclusion

  • HER2-positive recurrent or metastatic solid tumors for which there are no available curative treatment options.
  • Breast cancer and gastric/gastroesophageal junction cancers must have failed approved HER2-targeted agents.
  • Other HER2-positive tumor types must have failed standard of care therapies, while prior therapy with anti-HER2 drugs is not required.
  • Subject must be willing and able to undergo tumor tissue biopsy procedures
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • Subject has adequate bone marrow and organ function

Exclusion

  • HIV, active hepatitis B or hepatitis C infection.
  • Diagnosis of immunodeficiency or chronic exposure to systemic corticosteroid therapy or any other form of immunosuppressive therapy
  • Untreated or symptomatic central nervous system (CNS) metastases or cytology proven carcinomatous meningitis.
  • o Subjects with small, asymptomatic CNS metastases that do not require treatment are permitted to enroll.
  • Left ventricular ejection fraction (LVEF) \<50% as determined by ECHO or multiple gated acquisition scan (MUGA)
  • Other protocol-defined Inclusion/Exclusion may apply.
  • CT-0508 in Combination with Pembrolizumab Substudy Only:

Key Trial Info

Start Date :

February 2 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 31 2024

Estimated Enrollment :

48 Patients enrolled

Trial Details

Trial ID

NCT04660929

Start Date

February 2 2021

End Date

December 31 2024

Last Update

December 18 2024

Active Locations (7)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (7 locations)

1

City of Hope National Medical Center

Duarte, California, United States, 91010

2

UNC Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina, United States, 27599

3

OHSU Knight Cancer Institute

Portland, Oregon, United States, 97239

4

Abramson Cancer Center

Philadelphia, Pennsylvania, United States, 19104